- XORTX Therapeutics (XRX) has received approval to list its common shares on the TSXV effective as of the open of market on November 4 under the symbol XRTX
- Listing on the TSXV will increase the company’s visibility and access to domestic and institutional investors
- XORTX has submitted a request to voluntarily delist its common shares from the CSE
- XORTX Therapeutics Inc. is a biotechnology company working to create new therapeutics for kidney disease
- XORTX Therapeutics Inc. (XRX) opened trading at C$3.42 per share
XORTX Therapeutics (XRX) has received approval to list its common shares on the TSXV effective as of November 4, 2021.
The company’s common shares will be listed under the share symbol XRTX.
Dr. Allen Davidoff, XORTX’s President and CEO stated,
“Listing on the TSXV is another significant milestone for the company. This listing will further increase the company’s visibility and access to domestic and institutional investors.”
XORTX has submitted a request to voluntarily delist its common shares from the CSE. The delisting is expected to be effective on November 4.
Shareholders are not required to exchange their share certificates or take any other action in connection with the TSXV listing, as there will be no change in the trading symbol or CUSIP for the common shares.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development.
XORTX Therapeutics Inc. (XRX) opened trading at C$3.42 per share.